Announcing the approval, UCB said Kygevvi is a 2g/2g powder for oral solution and represents the first therapy available in the European Union beyond supportive care. The company noted that TK2d ...

A well-fitted ‘disguise’ allows transplanted mitochondria to slip into cells whose own mitochondria are defective, scientists ...

Researchers have developed a novel compound that could transform the way we treat Alzheimer's disease, offering not just a ...

Mitochondria are essential for cell survival, repair, and adaptation. Not only do they generate most of the energy needed during a cell's life, but they also regulate cell death, calcium balance, and ...

University of Lausanne researchers have identified a molecular mechanism explaining how cancer-fighting T cells become ...

Study of 2,197 patients with resistant depression finds 95 percent improved once parasympathetic and sympathetic ...

Nerve pain, tingling sensations, and burning feet used to be seen as untreatable symptoms of aging or diabetic ...

Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related ...

First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a ...

The team shows that transient low-dose bortezomib treatment during CAR-T cell manufacturing dampens proteasome-driven heme ...

In an era where blood-sugar supplements flood the market with exaggerated promises, Gluco Armor stands out for an ...

Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related ...